FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

FOCUS ON RESEARCH Previous Volume 355:1088-1091 September 14, 2006 Number 11 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Kappos, L. PubMed Citation

Multiple sclerosis is considered an autoimmune disease in which CD4+ T cells and macrophages destroy oligodendrocytes, which synthesize and maintain axonal myelin sheaths in the central nervous system (CNS). This misguided attack results in progressive focal demyelination that can cause severe neurologic disability. In this issue of the Journal, Kappos et al. (pages 1124–1140) report that the immunosuppressant fingolimod (also called FTY720 or 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol hydrochloride) exerted considerable therapeutic effects in a small, placebo-controlled clinical trial involving patients with relapsing multiple sclerosis. Patients who received oral fingolimod once daily had a rapid reduction in disease activity, reflected in significant reductions in . . . [Full Text of this Article]

Source Information

Dr. Massberg is a research fellow in pathology at Harvard Medical School and at the CBR Institute for Biomedical Research, Boston. Dr. von Andrian is a senior investigator at the CBR Institute for Biomedical Research and a professor of pathology at Harvard Medical School, Boston.

This article has been cited by other articles:

• Cohen, J. A. (2009). Emerging Therapies for Relapsing Multiple Sclerosis. Arch Neurol 66: 821-828 [Abstract] [Full Text]  
• Kersh, E. N., Luo, W., Adams, D. R., Mitchell, J., Garcia-Lerma, J. G., Butera, S., Folks, T., Otten, R. (2009). Evaluation of the lymphocyte trafficking drug FTY720 in SHIVSF162P3-infected rhesus macaques. J Antimicrob Chemother 63: 758-762 [Abstract] [Full Text]  
• Marsolais, D., Hahm, B., Edelmann, K. H., Walsh, K. B., Guerrero, M., Hatta, Y., Kawaoka, Y., Roberts, E., Oldstone, M. B. A., Rosen, H. (2008). Local Not Systemic Modulation of Dendritic Cell S1P Receptors in Lung Blunts Virus-Specific Immune Responses to Influenza. Mol. Pharmacol. 74: 896-903 [Abstract] [Full Text]  
• Shah, M. V., Zhang, R., Irby, R., Kothapalli, R., Liu, X., Arrington, T., Frank, B., Lee, N. H., Loughran, T. P. Jr (2008). Molecular profiling of LGL leukemia reveals role of sphingolipid signaling in survival of cytotoxic lymphocytes. Blood 112: 770-781 [Abstract] [Full Text]  
• Kovarik, J. M., Riviere, G.-J., Neddermann, D., Maton, S., Hunt, T. L., Schmouder, R. L. (2008). A Mechanistic Study to Assess Whether Isoproterenol Can Reverse the Negative Chronotropic Effect of Fingolimod. J Clin Pharmacol 48: 303-310 [Abstract] [Full Text]  
• Allende, M. L., Zhou, D., Kalkofen, D. N., Benhamed, S., Tuymetova, G., Borowski, C., Bendelac, A., Proia, R. L. (2008). S1P1 receptor expression regulates emergence of NKT cells in peripheral tissues. FASEB J. 22: 307-315 [Abstract] [Full Text]